Marco Boorsma, Forbion

With a ros­ter of gene ther­a­py vets, For­bion makes a bet on 'rel­a­tive­ly emp­ty space' of vec­tor­ized an­ti­bod­ies

The fu­ture waves of gene ther­a­py could look quite dif­fer­ent from the gene re­place­ment of­fer­ings cur­rent­ly on the mar­ket, For­bion reck­ons.

It’s the key idea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.